Abstract:Background: CD73-adenosine signaling in the tumor microenvironment is immunosuppressive and may be associated with aggressive renal cell carcinoma (RCC). We investigated the prognostic significance of CD73 protein expression in RCC leveraging nephrectomy samples. We also performed a complementary analysis using The Cancer Genome Atlas (TCGA) dataset to evaluate the correlation of CD73 (ecto-5'-nucleotidase (NT5E), CD39 (ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1)) and A2 adenosine receptor (A2AR; ADORA2A) transcript levels with markers of angiogenesis and antitumor immune response. Methods: Patients with RCC with available archived nephrectomy samples were eligible for inclusion. Tumor CD73 protein expression was assessed by immunohistochemistry and quantified using a combined score (CS: % positive cells×intensity). Samples were categorized as CD73negative (CS=0), CD73low or CD73high (< and ≥median CS, respectively). Multivariable Cox regression analysis compared disease-free survival (DFS) and overall survival (OS) between CD73 expression groups. In the TCGA dataset, samples were categorized as low, intermediate and high NT5E, ENTPD1 and ADORA2A gene expression groups. Gene expression signatures for infiltrating immune cells, angiogenesis, myeloid inflammation, and effector T-cell response were compared between NT5E, ENTPD1 and ADORA2A expression groups. Results: Among the 138 patients eligible for inclusion, 'any' CD73 expression was observed in 30% of primary tumor samples. High CD73 expression was more frequent in patients with M1 RCC (29% vs 12% M0), grade 4 tumors (27% vs 13% grade 3 vs 15% grades 1 and 2), advanced T-stage (≥T3: 22% vs T2: 19% vs T1: 12%) and tumors with sarcomatoid histology (50% vs 12%). In the M0 cohort (n=107), patients with CD73high tumor expression had significantly worse 5-year DFS (42%) and 10-year OS (22%) compared with those in the CD73negative group (DFS: 75%, adjusted HR: 2.7, 95% CI 1.3 to 5.9, p=0.01; OS: 64%, adjusted HR: 2.6, 95% CI 1.2 to 5.8, p=0.02) independent of tumor stage and grade. In the TCGA analysis, high NT5E expression was associated with significantly worse 5-year OS (p=0.008). NT5E and ENTPD1 expression correlated with higher regulatory T cell (Treg) signature, while ADORA2A expression was associated with increased Treg and angiogenesis signatures. Conclusions: High CD73 expression portends significantly worse survival outcomes independent of stage and grade. Our findings provide compelling support for targeting the immunosuppressive and proangiogenic CD73-adenosine pathway in RCC.

CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy

Integrative Analyses Identify CD73 As a Prognostic Biomarker and Immunotherapeutic Target in Intrahepatic Cholangiocarcinoma.

Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers

Intratumoral CD73: an Immune Checkpoint Shaping an Inhibitory Tumor Microenvironment and Implicating Poor Prognosis in Chinese Melanoma Cohorts

Expression and Prognostic Impact of CD73 in Classical Hodgkin Lymphoma

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma

Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival

The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients

Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review.

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.

Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma

The CD73 immune checkpoint promotes tumor cell metabolic fitness

CD73 Promotes Hepatocellular Carcinoma Progression and Metastasis Via Activating PI3K/AKT Signaling by Inducing Rap1-mediated Membrane Localization of P110β and Predicts Poor Prognosis

Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance

Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC).

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer.

Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer

Analysis of the expression of cytokines and chemokines, platelet-leukocyte aggregates, sCD40L and sCD62P in cutaneous melanoma

CD72, a new immune checkpoint molecule, is a novel prognostic biomarker for kidney renal clear cell carcinoma